On August 23, 2022 Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), reported that the company’s interim report for January–June 2022 is now available on the company’s website, www.isofolmedical.com (Press release, Isofol Medical, AUG 23, 2022, View Source [SID1234618562]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The information in the press release is intended for investors.

Second quarter, April–June 2022
Net revenue amounted to TSEK 4,027 (7,333) and other revenue to TSEK 0 (0)
The result for the period amounted to TSEK -54,033 (-45,394)
Earnings per share amounted to SEK -0.33 (-0.48)
Cash and cash equivalents at June 30 amounted to TSEK 277,727 (530,682)
First half of the year, January-June 2022
Net revenue amounted to TSEK 8,033 (12,548) and other revenue to TSEK 1 (0)
The result for the period amounted to TSEK -101,907 (-88,055)
Earnings per share amounted to SEK -0.63 (-0.99)
Significant events during the second quarter 2022
On April 22, it was announced that the analysis process of study data from the AGENT study had begun.
Jan Törnell was elected as new Chairman of the Board of the company in conjunction with the Annual General Meeting on May 19.
Significant events after the event of the period
On August 3, Isofol presented the topline results of the global pivotal AGENT study in advanced colorectal cancer. The data revealed that the study did not achieve the primary endpoint of objective response rate (ORR) or the key secondary endpoint of progression-free survival (PFS).
In July, Isofol received approval of a biomarker analysis patent.
CEO´s comment:
" It is incredibly disappointing that the results from the top-line analysis did not demonstrate the advantages we had hoped for. Final data and sub-group analyses will be decisive for the final assessment of our application options. I would like to point out that Isofol has a strong financial position, which will enable us to complete the AGENT study and analyze the final data in an efficient and reliable manner. This is very important in the situation we now find ourselves in.", says CEO Ulf Jungnelius.

Audiocast, August 23, at 12:30 p.m. CEST
In conjunction with the publication of the interim report for the second quarter of 2022, Isofol invites investors, analysts, and media to an audiocast on August 23, 2022 at 12:30 p.m. CEST. The presentation will be held by Isofol´s CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment the report, followed by a Q&A-session. The presentation will be held in English.

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST, on August 23, 2022.